Drug intelligence / Profile preview

UI15AML055MT

Development stage: Phase 1
Lead developer: Korea United Pharm
Modality: Small Molecules
Administration: Oral

Overview

UI15AML055MT is an investigational drug developed by Korea United Pharm. Inc. It is currently undergoing a Phase 1 clinical trial to evaluate its safety and pharmacokinetic profiles following a single oral administration in healthy male volunteers. The study compares UI15AML055MT to Amosartan® tablet 5/50 mg, suggesting its potential use in cardiovascular conditions, likely hypertension, although the specific indication is not explicitly stated.

Beyond the preview

Go deeper on UI15AML055MT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UI15AML055MT.

Explore the full profile